PLoS ONE (Jan 2016)

Different Antibody Response against the Coxsackievirus A16 VP1 Capsid Protein: Specific or Non-Specific.

  • Yingying Ding,
  • Zhihong Wang,
  • Xi Zhang,
  • Zheng Teng,
  • Caixia Gao,
  • Baohua Qian,
  • Lili Wang,
  • Jiaojiao Feng,
  • Jinhong Wang,
  • Chunyan Zhao,
  • Cunjiu Guo,
  • Wei Pan

DOI
https://doi.org/10.1371/journal.pone.0162820
Journal volume & issue
Vol. 11, no. 9
p. e0162820

Abstract

Read online

Coxsackievirus A16 (CA16) is one of the major causative agents of hand, foot, and mouth disease worldwide. The non-neutralizing antibody response that targets CA16 VP1 remains poorly elucidated. In the present study, antibody responses against CA16 VP1 in Shanghai blood donors and Shanxi individuals were analyzed by ELISA and inhibitory ELISA using five CA16 VP1 antigens: VP11-297, VP141-297, VP11-60, VP145-58 and VP161-297. The correlation coefficients for most of the reactions against each of the five antigens and the inhibition of the anti-CA16 VP1 antibody response produced by the various antigens were higher in Shanghai blood donors compared to those in Shanxi individuals. VP11-297 and VP141-297 strongly inhibited the anti-CA16 VP1 response in serum samples from both populations, while VP145-58 and VP161-297 intermediately and weakly inhibited the anti-CA16 VP1 response, respectively, in only Shanghai group. A specific type of inhibition (anti-CA16 VP1 was completely inhibited by both VP11-60 and VP141-297) characterized by high neutralizing antibody titers was identified and accounted for 71.4% of the strongly reactive samples from the Shanghai group. These results indicate that the Shanghai blood donors exhibited a consistent and specific antibody response, while the Shanxi individuals showed an inconsistent and non-specific antibody response. These findings may improve the understanding of host humoral immunity against CA16 and help to identify an effective approach for seroepidemiological surveillance and specific diagnosis of CA16 infection based on normal and competitive ELISA.